Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

Executive Summary: Lopinavir (ABT-378) is a highly potent HIV protease inhibitor with inhibition constants (K_i) of 1.3–3.6 pM against both wild-type and mutant HIV proteases, including Val82 variants (ApexBio). It maintains an EC₅₀ below 0.06 μM for Val82 mutants, demonstrating reduced serum protein sensitivity compared to ritonavir. Lopinavir is effective in nanomolar ranges (4–52 nM) in cell-based assays and achieves a 14-fold increase in plasma exposure when co-administered with ritonavir. Its cross-pathogen activity extends to coronaviruses such as MERS-CoV at low micromolar EC₅₀ values (de Wilde et al., 2014).

Biological Rationale

Lopinavir is a synthetic protease inhibitor designed to target the HIV-1 protease enzyme. HIV protease is essential for viral maturation and infectivity, cleaving the Gag-Pol polyprotein into functional viral proteins. Inhibition of this enzyme leads to the production of immature, non-infectious viral particles (see mechanistic review). Lopinavir was engineered as a ritonavir analog with modifications to reduce resistance, specifically at the Val82 residue, a known mutation site conferring drug resistance in HIV (ApexBio).

Lopinavir's robust inhibition profile makes it a valuable tool in research focused on HIV infection pathways, antiretroviral therapy development, and evaluation of resistance mechanisms. Its favorable pharmacokinetics and serum stability enable reliable results in HIV protease inhibition assays and related antiviral research workflows.

Mechanism of Action of Lopinavir

Lopinavir competitively inhibits the active site of HIV-1 protease, a dimeric aspartyl protease required for viral polyprotein processing. By binding the enzyme, Lopinavir prevents cleavage of the Gag-Pol polyprotein, a critical step for viral maturation. The compound exhibits a K_i of 1.3–3.6 pM for wild-type and mutant HIV proteases, markedly inhibiting both forms under physiologically relevant conditions (ApexBio).

Lopinavir's structural design, with reduced interaction at the Val82 site, allows it to retain efficacy against resistant strains selected by ritonavir. Unlike ritonavir, Lopinavir's antiviral activity is only modestly affected by human serum proteins, preserving approximately 10-fold greater potency in the presence of serum. This property is crucial for realistic in vitro and in vivo modeling of drug efficacy.

Evidence & Benchmarks

• Lopinavir inhibits wild-type and Val82 mutant HIV-1 protease with K_i values in the 1.3–3.6 pM range (ApexBio).
• EC₅₀ for Val82 mutant strains is <0.06 μM in enzymatic inhibition assays (ApexBio).
• Demonstrates 10-fold greater antiviral potency in the presence of human serum compared to ritonavir (ApexBio).
• In cell-based assays, Lopinavir is active at 4–52 nM concentrations, even in the presence of multidrug-resistant HIV (internal study).
• Oral administration in animal models (10 mg/kg) leads to C_max of 0.8 μg/mL and 25% bioavailability; plasma levels decrease below quantitation by 6 h post-dose (ApexBio).
• Co-administration with ritonavir increases Lopinavir AUC by 14-fold, enhancing systemic exposure (ApexBio).
• Lopinavir inhibits MERS-CoV replication in cell culture with EC₅₀ values of 3–8 μM, and also suppresses SARS-CoV and HCoV-229E (de Wilde et al., 2014).

Applications, Limits & Misconceptions

Lopinavir is widely used in HIV protease inhibition assays, resistance profiling, and antiviral drug development. It is also employed in cross-pathogen studies for coronaviruses and other viral families. The A8204 kit (ApexBio) provides a research-grade standard for these applications.

Compared to prior literature, this article extends the discussion in Immuneland's review by providing updated quantitative benchmarks for serum stability and resistance profiles.

Common Pitfalls or Misconceptions

• Lopinavir is not water-soluble: It is soluble at ≥31.45 mg/mL in DMSO and ≥48.3 mg/mL in ethanol, but insoluble in water (ApexBio).
• Not a cure for HIV infection: Lopinavir inhibits HIV replication but does not eradicate latent reservoirs.
• Limited clinical efficacy against coronaviruses: Although effective in cell culture, clinical translation for MERS-CoV or SARS-CoV remains unproven (de Wilde et al., 2014).
• Serum stability is superior to ritonavir but not absolute: Some loss of potency occurs in high-serum environments.
• Requires co-administration with ritonavir for optimal exposure in vivo: As a CYP3A4 substrate, Lopinavir is rapidly metabolized unless co-dosed with ritonavir.

Workflow Integration & Parameters

Lopinavir is supplied as a solid with a molecular weight of 628.81 g/mol and formula C₃₇H₄₈N₄O₅. Solutions should be prepared fresh in DMSO or ethanol at ≥31.45 mg/mL and ≥48.3 mg/mL, respectively. Store aliquots at -20°C for short-term use to maintain stability and activity (ApexBio).

For cell-based HIV protease inhibition assays, working concentrations typically range from 4–52 nM. In animal studies, oral dosing at 10 mg/kg is standard, with attention to rapid systemic clearance unless ritonavir is included. The workflow benefits from Lopinavir’s robust serum stability, enabling reproducible results in physiologically relevant conditions. See this mechanistic update for further discussion on resistance and serum effects, extending the present article's focus on experimental parameters.

Conclusion & Outlook

Lopinavir (ABT-378) remains a gold standard for HIV protease inhibition due to its potent activity against both wild-type and resistant HIV strains, superior serum stability, and validated cross-pathogen potential. Ongoing research is clarifying its translational scope in emerging viral infections, while best practices for workflow integration further enhance its reliability for antiviral research (see comparative review for broader context). For detailed product specifications and ordering, refer to the Lopinavir A8204 kit page.